Camilo Colaco

ImmunoBiology

Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.

dont miss

The immunobiology of immunotherapy

Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.

EVEN MORE SEMINARS

  • Glenn Flux: Speaking at the Oncology Convention

    Glenn Flux
    Royal Marsden Hospital

    The emergence and resurgence of radiotherapeutics for cancer treatment

  • Nizar Asadi: Speaking at the Oncology Convention

    Nizar Asadi
    Royal Brompton & Harefield NHS Foundation Trust

    Thoracic surgery in the treatment of lung cancer

  • Dr Ndaba Mazibuko: Speaking at the Oncology Convention

    Dr Ndaba Mazibuko
    Care Oncology Clinic, Kings College London

    Drug Repurposing In Practice: Metabolic Pleiotropism in Glioblastoma Management

  • Philip Beer MRCP, FRCPath, PhD: Speaking at the Oncology Convention

    Philip Beer MRCP, FRCPath, PhD
    ONCODNA S.A

    The evolution of oncology therapeutics in the genomic era.

  • Michael Schreiber: Speaking at the Oncology Convention

    Michael Schreiber
    Brain Tumor Foundation, Chairman

    Brain Tumors - Innovation, support and advocacy